ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A planned 5-year cohort focused on newly diagnosed Crohn’s patients could identify patterns of bowel damage and predictors of surgery or disability, which may eventually help tailor treatments and monitoring.
Who Should Pay Attention
Adults newly diagnosed with Crohn’s disease; gastroenterologists and radiologists involved in IBD care; researchers studying disease progression, imaging biomarkers, and long-term outcomes.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment533 participants
Study statusActive_not_recruiting
Source depthTrial registry record
What To Know
The CROCO Study is a prospective, multicenter cohort enrolling adults newly diagnosed with Crohn’s disease to follow disease anatomy and progression using the Lémann Index over 5 years.
Patients receive standard-of-care treatments with scheduled imaging (magnetic resonance enterography/abdominal MRI) at years 1, 3, and 5; ileocolonoscopy, upper endoscopy, and pelvic MRI are included based on disease location.
The registry will collect clinical and lab markers, surgeries, and a yearly disability index, and plans centralized training to standardize Lémann Index assessment. This entry summarizes the registered trial record (ClinicalTrials.gov).
It describes study design, planned enrollment, imaging and endoscopic assessments, outcomes (Lémann Index at years 1, 3, 5), and planned follow-up but does not report results or effectiveness of specific therapies.
What the study means for patients: the cohort aims to improve understanding of how bowel damage develops early in Crohn’s disease and which factors predict progression and disability. It may inform future biomarkers or treatment strategies, but participants receive usual care and the record does not present findings.
Keep In Mind
This is a trial record (ClinicalTrials.gov) describing planned methods and endpoints, not results. The Lémann Index is an imaging-based measure of cumulative bowel damage; MRI at Year 1 may not be performed for all patients and is the only procedure that may occur outside routine care.
Enrollment and follow-up are planned prospectively; no efficacy or outcome data are reported in the registry entry.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorGLSMED Learning Health S.A.
Trial IDNCT05420233
Study typeInterventional
Trial phaseNA
Enrollment533 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 28, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
RedHill Biopharma announces plans to advance program for Crohn's disease
This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...